Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA.
Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA; Providence Medical Research Center, Providence Health Care, Spokane, WA, USA.
Psychiatry Res. 2018 Feb;260:233-235. doi: 10.1016/j.psychres.2017.11.070. Epub 2017 Nov 29.
We examined whether the interaction of baseline stimulant use, assessed by urine drug tests, and type of serious mental illness (SMI) diagnosis predicted stimulant use in a trial of contingency management (CM). The interaction between baseline stimulant use and SMI diagnoses was significant in the overall sample (p=0.002) when controlling for the main effects of treatment condition, baseline stimulant use, and SMI diagnosis. Similar results were also found within the CM sample. Individuals with bipolar disorder were more or less likely, depending on their baseline stimulant-drug test results, to use stimulants during treatment compared to those with other SMI diagnoses.
我们考察了基线兴奋剂使用(通过尿液药物检测评估)与严重精神疾病(SMI)诊断类型之间的相互作用,是否能预测在一项基于条件强化管理(CM)的试验中的兴奋剂使用情况。在控制了治疗条件、基线兴奋剂使用和 SMI 诊断的主要影响后,整体样本中基线兴奋剂使用和 SMI 诊断之间的交互作用具有统计学意义(p=0.002)。在 CM 样本中也发现了类似的结果。与其他 SMI 诊断相比,双相情感障碍患者在基线兴奋剂药物检测结果的基础上,更有可能在治疗期间使用兴奋剂。